DB
NPCE icon

Dmitry Balyasny’s Neuropace NPCE Stock Holding History

Dmitry Balyasny’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-23,350
Closed -$307K – 3353
2026
Q1 		$307K Buy
+23,350
New +$350K ﹤0.01% 2555
2025
Q2 		– Sell
-22,289
Closed -$279K – 3186
2025
Q1 		$274K Buy
+22,289
New +$279K ﹤0.01% 2483
2024
Q2 		– Sell
-26,950
Closed -$356K – 2937
2024
Q1 		$356K Sell
26,950
-206
-0.8% -$2.94K ﹤0.01% 2193
2023
Q4 		$280K Buy
+27,156
New +$217K ﹤0.01% 2189

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Dmitry Balyasny's NPCE Position: Q2 2026 in Review

Dmitry Balyasny sold out of Neuropace (NPCE) in Q2 2026, closing a stake of 23,350 shares — an estimated $307K sold.

Dmitry Balyasny first reported a position in NPCE in Q4 2023 and held it in 4 quarters. The position peaked at $356K in Q1 2024. 112 funds tracked by Wall St. Rank hold NPCE as of Q2 2026.

  • Dmitry Balyasny reported no remaining Neuropace position as of Q2 2026 after selling out during the quarter.
  • Dmitry Balyasny sold 23,350 Neuropace shares in Q2 2026, an estimated $307K.
  • Dmitry Balyasny first reported a position in Neuropace in Q4 2023 and held it in 4 quarters.
  • Dmitry Balyasny's Neuropace position peaked at $356K in Q1 2024.
  • 112 funds tracked by Wall St. Rank held Neuropace as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.